Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist

British Journal of Pharmacology

Volumn 130, Issue 6, 2000, Pages 1418-1424

  Cunha, J M ^a   Cunha, F Q ^a   Poole, S ^a,b   Ferreira, S H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Bradykinin; Inflammatory hyperalgesia; Interleukin 1 receptor antagonist; Interleukin 1 ; Interleukin 8; Tumour necrosis factor alpha

Indexed keywords

ACETIC ACID; BRADYKININ; CARRAGEENAN; DOPAMINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033928937     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703434     Document Type: Article

References (43)

1. AIURA, K., GELFAND, J.A., BURKE, J.F., THOMPSON, R.C. & DINARELLO, C.A. (1993). Interleukin-1 (IL-I) receptor antagonist prevents Staphylococcus epidermis-induced hypotension and reduces circulating levels of tumour necrosis factor and IL-1 beta in rabbits. Infect. Immun., 61, 3342-3350.
2. AREND, W.P., MALYAK, M., GUTHRIDGE, C.J. & GABAY, C. (1998). Interleukin-1 receptor antagonist: role in biology. Ann. Rev. Immunol., 16, 27-55.
3. AREND, W.P., WELGUS, H.G., THOMPSON, R.C. & EISENBERG, S.P. (1990). Biological properties of recombinant human myocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest., 85, 1694-1697.
4. BANNER, L.R., PATTERSON, P., ALLCHORNE, A., POOLE, S. & WOOLF, C.J. (1998). Leukaemia inhibitory factor is an anti-inflammatory and analgesics cytokine. J. Neurosci., 18, 5456-4262.
5. COLLIER, H.O.J., DINNEEN, J.C., JOHNSON, C.A. & SCHNEIDER, C. (1968). The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br. J. Pharmacol. Chemother., 32, 295-310.
6. COLOTTA, F., RE., F., MUZIO, M., BERTINI, R., POLENTARUTTI, N., SIRONI, M,. GIRI, J., DOWLER, S.K., SIMS, J.E. & MANTOVANI, A. (1993). Interleukin-1 type II receptors: a decoy target for IL-1 that is regulated by IL-4. Science, 261, 472-475.
7. CUNHA, F.Q., POOLE, S., LORENZETTI, B.B. & FERREIRA, S.H. (1991). Interleukin-8 as a mediator of sympathetic pain. Br. J. Pharmacol., 104, 765-767.
8. CUNHA, F.Q., POOLE, S., LORENZETTI, B.B. & FERREIRA, S.H. (1992). The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br. J. Pharmacol., 107, 660-664.
9. CUNHA, F.Q., POOLE, S., LORENZETTI, B.B. & VEIGA, F.H. & FERREIRA, S.H. (1999). Cytokine mediated inflammatory hyperalgesia limited by interleukin-4. Br. J. Pharmacol., 126, 45-50.
10. DINARELLO, C.A. & THOMPSON, R.C. (1991). Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today, 12, 404-410.
11. DUBOST, J.J., SOUBRIER, M., RISTORI, J.M., BEAUJON, G., OUALID, T., BUSSIÈRE, J.L. & SAUVEZIE, B. (1997). An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis. Rev. Rhum. Engl. Ed., 64, 789-793.
12. EISENBERG, S.P., EVANS, R.J., AREND, W.P., VERDERBER, E., BREWER, M.T., HANNUM, C.H. & THOMPSON, R.C. (1990). Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature, 343, 341-346.
13. FERREIRA, S.H., LORENZETTI, B.B., BRISTOW, A.F. & POOLE, S. (1988). Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature, 334, 698-700.
14. FERREIRA, S.H., LORENZETTI, B.B. & CORREA, F.M.A. (1978). Central and peripheral antialgesic action of aspirin like drug. Eur. J. Pharmacol., 53, 39-48.
15. FERREIRA, S.H., LORENZETTI, B.B. & POOLE, S. (1993). Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br. J. Pharmacol., 110, 1227-1231.
16. FISCHER, E., MARANO, M.A., VAN ZEE, K.J., ROCK, C.S., HAWES, A.S., THOMPSON, W.A., DEFORGE, L., KENNEDY, J.S., REMICK, D.G., BLOEDOW, D.C., THOMPSON, R.C., LOWRY, S.F. & MOLDAWER, L.L. (1992). Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host response to sublethal endotoxemia. J. Clin. Invest., 89, 1551-1557.
17. GOEHLER, L.E., RELTON, J.K., DRIPPS, D., KIECHLE, R., TARTAGLIA, N., MAIER, S.F. & WATKINS, L.R. (1997). Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain. Res. Bull., 43, 357-364.
18. GORIZONTOVA, M.P. & MIRONOVA, I.V. (1995). The effect of prophylactic administration of pentoxifyllin (trental) on development of a neuropathic pain syndrome and microcirculatory disorders caused by it. Biull. Eksp. Biol. Med., 119, 485-487.
19. GRANOWITZ, E.V., CLARK, B.D., MANCILLA, J. & DINARELLO, C.A. (1991a). Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J. Biol. Chem., 266, 14147-14150.
20. GRANOWITZ, E.V., SANTOS, A.A., POUTSIAKA, D.D., CANNON, J.G., WILMORE, D.W., WOLFF, S.M. & DINARELLO, C.A. (1991b). Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet, 338, 1423-1424.
21. KOSTER, R., ANDERSON, M. & DE BEER, E.J. (1959). Acetic acid for analgesic screening. Federation Proc., 18, 412.
22. LUMPKIN, M.D. (1987). The regulation of ACTH secretion by IL-1. Science, 238, 452-545.
23. MCINTYRE, K.M., STEPAN, G.J., KOLINSKY, K.D., BENJAMIN, W.R., PLOCINSKI, J.M., KAFFKA, K.L., CAMPEN, C.A., CHIZZONITE, R.A. & KILIAN, P.L. (1991). Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med., 173, 931-939.
24. MILLER, A.J., LUHESI, G.N., ROTHWELL, N.J. & HOPKINS, S.J. (1997). Local cytokine induction by LPS in the rat air pouch and its relationship to the febrile response. Am. J. Physiol., 272, R857-861.
25. MORSTYN, G. & BURGESS, A.W. (1988). Hemopoietic growth factors: a review. Cancer Res., 48, 5624-5637.
26. OHLSSON, K., BJORK, P., BERGENFELDT, M., HAGEMAN, R. & THOMPSON, R.C. (1990). Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature, 348, 550-552.
27. OHTSUKA, H., HIGUCHI, T., MATSUZAWA, H., SATO, H., TAKAHASHI, K., TAKAHASHI, J. & YOSHINO, T. (1997). Inhibitory effect on LPS-induced tumour necrosis factor, in calves treated with chlorpromazine or pentoxifylline. J. Vet. Med. Sci., 59, 1075-1077.
28. OPP, M.R. & KRUEGER, J.M. (1991). Interleukin-1 receptor antagonist blocks interleukin-1 induced sleep and fever. Am. J. Physiol., 260, R453-457.
29. POOLE, S., BRISTOW, A.F., LORENZETTI, B.B,. DAS, R.E., SMITH, T.W. & FERREIRA, S.H. (1992). Peripheral analgesic activities of peptides related to alpha-melanocyte stimulating hormone and interleukin-1 beta 193-195. Br. J. Pharmacol., 106, 489-492.
30. POOLE, S., CUNHA, F.Q., SELKIRK, S., LORENZETTI, B.B. & FERREIRA, S.H. (1995). Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1. Br. J. Pharmacol., 115, 684-688.
31. POOLE, S., LORENZETTI, B.B., CUNHA, J.M., CUNHA. F.Q. & FERREIRA, S.H. (1999). Bradykinin B1 and B2 receptors, tumor necrosis factor a and inflammatory hyperalgesia. Br. J. Pharmacol., 126, 649-656.
32. REES, G, GEE, C.K., WARD. H.L., BALL, C., TARRANT, G.M., POOLE, S. & BRISTOW, A.F. (1999). Rat tumour necrosis factor-α: expression in recombinant picia pastoris, purification, characterization and development of a novel ELISA. Eur. Cytokine Netw., 10, 383-392.
33. RIBEIRO. R.A., VALE, M.L., THOMAZZI, S.M., PASCHOALATO, A.B.P., POOLE, S., FERREIRA, S.H. & CUNHA, F.Q. (2000). Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur. J. Pharmacol., 387, 111-118.
34. SAFIEH-GARABEDIAN, B., KANAAN, S.A., JALAKHIAN, R.H., JABBUR, S.J. & SAADE, N.E. (1997). Involvement of interleukin-1 beta, nerve growth factor, and prostaglandin-E2 in the hyperalgesia induced by intraplantar injections of low doses of thymulin. Brain Behav. Immun., 11, 185-200.
35. SAFIEH-GARABEDIAN, B., POOLE, S., ALLCHORNE, A., WINTER, J. & WOOLF, C.J. (1995). Interleukin-1 beta contributes to the inflammation-induced increase in nerve-growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol., 115, 1265-1275.
36. SAMPAIO, E.P., SARNO, E.N., GALILLY, R., KOHN, Z.A. & KAPLAN, Z. (1991). Thalidomide selectively inhibits tumour necrosis factor-χ production by stimulated human monocytes. J. Exp. Med., 173, 699-703.
37. SOMMER, C., MARZINIAK, M. & MYERS, M.M. (1998). The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain, 74, 83-91.
38. STEFFERL, A., HOPKINS, S.J., ROTHWELL, N.J. & LUHESHI, G.N. (1996). The role of TNF-alpha in fever: opposing actions of human and murine TNF-alpha and interactions with IL-beta in the rat. Br. J. Pharmacol., 118, 1919-1924.
39. WATKINS, E.R., GOEHLER, L.E., RELTON, J., BREWER, M.T. & MAIER, S.F. (1995). Mechanism of tumour necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain-Res., 692, 244-250.
40. WATKINS, L.R., WIERTELAK, E.P., GOEHLER, L.E., SMITH, K.P., MARTIN. D. & MAIER, S.F. (1994). Characterization of cytokine induced hyperalgesia. Brain Res., 654, 15-26.
41. WEINBERG, J.B., MASON, S.N. & WORTHAM, T.S. (1992). Inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) messenger RNA (mRNA) expression in HL-60 leukemia cells by pentoxifylline and dexamethasone: dissociation of acivicin-induced TNF-alpha and IL-1 beta mRNA expression from acivicin-induced monocytoid differentiation. Blood, 79, 3337-3343.
42. WOOLF, C.J., ALLCHORNE. A., SAFIEH-GARABEDIAN, B. & POOLE, S. (1997). Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br. J. Pharmacol., 121, 417-424.
43. WOOLF, C.J., QING-PING, M.A., ALLCHORNE, A. & POOLE, S. (1996). Peripheral cell types contributing to the hyperalgesic action of the nerve growth factor in inflammation. J. Neurosci., 16, 2716-2723.